Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

8.2K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

734
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
734
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

14.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.7K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The role of allogeneic stem cell transplantation in peripheral T-cell lymphoma.

Bone marrow transplantation·2026
Same author

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

EClinicalMedicine·2026
Same author

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026
Same author

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

Bone marrow transplantation·2026

関連する実験動画

Updated: Dec 25, 2025

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

413

急性リンパ性白血病

Florent Malard1, Mohamad Mohty1

  • 1Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France; Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France.

Lancet (London, England)
|April 6, 2020
PubMed
まとめ
この要約は機械生成です。

急性リンパ性白血病 (ALL) は子供と成人に影響し,遺伝的変化が予後に影響します. リスクの階層化と免疫療法の進歩により 治療の成果が向上する見込みです

さらに関連する動画

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

関連する実験動画

Last Updated: Dec 25, 2025

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

413
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

科学分野:

  • 血液学
  • 腫瘍学
  • 遺伝学

背景:

  • 急性リンパ性白血病 (ALL) は,リンパ前駆体細胞の遺伝的変異によって特徴づけられる,子供および成人の一般的な癌です.
  • 予後要因は稀ですが,染色体異常や遺伝的変異はALLの主要な予後指標です.
  • 現行の治療法では若年患者の治療結果が改善されますが,高齢者や再発または耐性疾患の患者は予後不良です.

研究 の 目的:

  • 急性リンパ性白血病 (ALL) の病原性,予後,および治療に関する現在の理解を要約します.
  • 遺伝的要因とリスクの階層化が ALL の結果に与える影響を強調する.
  • ALL治療の新たな免疫療法戦略について議論する.

主な方法:

  • 急性リンパ性白血病 (ALL) の疫学,遺伝学,治療結果に関する既存の文献のレビュー.
  • 染色体異常や遺伝子変異を含む予後要因の分析
  • 化学療法と免疫療法を含む現在の治療方法と新しい治療法の検討

主要な成果:

  • ALLの発生率は1歳から4歳の間でピークに達し,遺伝的変異は細胞の分化と増殖に不可欠です.
  • リスクの階層化と強化された化学療法により,特に小児および若年成人ALLの治療結果が改善されました.
  • 高齢者および再発性/耐性ALLの患者のアウトカムは依然として困難です.

結論:

  • 遺伝的変異はALLの発症と予後において中心的であり,リスクの階層化と治療の強さを指し示している.
  • 化学療法により治療結果が改善されていますが CAR T細胞やモノクローナル抗体は ALL治療の未来です
  • 全てのALL患者グループ,特に高齢者および耐性疾患患者の生存率を改善するために,免疫療法戦略に関するさらなる研究が不可欠です.